OBJECTIVE: To investigate the feasibility of dynamic contrast-enhanced MRI ( @entity9243 -MRI) and diffusion-weighted MRI (DWI) in monitoring early therapeutic response to @entity2857 in @entity1358 ( @entity1358 ) xenograft models. METHODS: @entity2857 (40   mg   kg(-1)) was administered orally to BALB/c @entity19 (n   =   9) bearing subcutaneous @entity5 of @entity1 @entity1358 ACHN xenografts. @entity9243 -MRI and DWI were obtained 0, 1, 3 and 7 days after therapy, and @entity9243 -MRI parameters (K(trans) and ve) and apparent diffusion coefficient (ADC) values were calculated. Tumour size and volume changes were correlated with changes in @entity9243 -MRI parameters or ADC values after therapy. RESULTS: Following therapy, K(trans) showed a significant decrease over time (p   =   0.005), whereas ve did not demonstrate significant changes between time points (p   =   0.97). ADC values showed a progressive increase over time (p   =   0.004). Compared with pre-therapy, K(trans) showed a significant decrease after 3 days of therapy (p   =   0.039), and ADC values increased significantly after 7 days (p   =   0.039). Tumour size and volume did not show significant changes during 7 days. Tumour size and volume changes were not associated with changes in @entity9243 -MRI parameters or ADC values. CONCLUSION: @entity9243 -MRI and DWI may show early physiological changes within 1 week after initiating @entity2857 treatment on @entity1 @entity1358 xenografts. ADVANCES IN KNOWLEDGE: The quantitative parameters of @entity9243 -MRI and DWI may offer the potential for assessing early therapeutic response to @entity2857 in clinical trials.

Assessment of early therapeutic response to XXXX in @entity1358 xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.

@entity1 :: ('9606', 'Species') :: ['human'] @entity19 :: ('10090', 'Species') :: ['nude mice'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours'] @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib', 'Sorafenib'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma', 'RCC'] @entity9243 :: ('D010936', 'Chemical') :: ['DCE']
@entity2857 :: (MESH:C471405,Chemical) :: ['sorafenib']
